Financials in USD. Standardized financial statements.
A compact view of how Catalyst Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $588.99M | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M | $102.31M | $500,000 | $0 | $0 |
| Revenue Growth? | +19.8% | +23.5% | +85.9% | +52.1% | +18.3% | +16.4% | +20361.2% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $87.25M | $68.84M | $51.97M | $34.39M | $21.88M | $17.04M | $14.76M | $19.92M | $45,689 | $43,406 |
| Gross Profit? | $501.74M | $422.89M | $346.24M | $179.81M | $118.95M | $102.03M | $87.55M | -$19.42M | -$45,689 | -$43,406 |
| Gross Margin? | +85.2% | +86.0% | +86.9% | +83.9% | +84.5% | +85.7% | +85.6% | -3883.8% | 0.0% | 0.0% |
| Operating Expenses? | $243.96M | $227.76M | $259.43M | $77.97M | $66.56M | $60.73M | $55.72M | $35.80M | $18.68M | $19.28M |
| Operating Income? | $257.78M | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M | $31.82M | -$35.30M | -$18.68M | -$19.28M |
| EBITDA? | $295.65M | $232.90M | $119.69M | $103.08M | $52.58M | $41.40M | $31.88M | -$35.26M | -$18.49M | -$18.03M |
| Income Before Tax | $283.51M | $216.26M | $94.51M | $104.72M | $52.67M | $41.89M | $33.41M | -$34.00M | -$18.41M | -$18.07M |
| Income Tax Expense | $69.19M | $52.37M | $23.10M | $21.64M | $13.19M | -$33.09M | $1.53M | $0 | $141,215 | $0 |
| Net Income? | $214.33M | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M | $31.88M | -$34.00M | -$18.41M | -$18.07M |
| EPS? | $1.75 | $1.38 | $0.67 | $0.80 | $0.38 | $0.72 | $0.31 | $-0.33 | $-0.21 | $-0.22 |
| Diluted EPS? | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 | $0.71 | $0.30 | $-0.33 | $-0.21 | $-0.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality